Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 24, Issue 3, 1998, Pages 465-477

  O'Dell, J R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0031670893     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70020-X     Document Type: Article

References (19)

1. M. Boers A.C. Verhoeven H.M. Markusse Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 1997 309 318
2. M.J. Elliott R.N. Maini M. Feldman Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
3. D.T. Felson J.J. Anderson M. Boers The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis Rheum 36 1993 729 740
4. D.T. Felson J.J. Anderson R.F. Meenan The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis Arthritis Rheum 37 1994 1487 1491
5. M. Kloppenburg F.C. Breedveld J.P. Terwiel Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial Arthritis Rheum 37 1994 629 636
6. L.W. Moreland S.W. Baumgartner M.H. Schiff Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 1997 141 147
7. S.L. Morgan J.E. Baggott W.H. Vaughn Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial Ann Intern Med 121 1994 833 841
8. J. O'Dell Combination DMARD therapy for rheumatoid arthritis: Apparent universal acceptance Arthritis Rheum 40 suppl 9 1997 50
9. J. O'Dell C. Haire W. Drymalski Methotrexate (M)=Sulfasalazine (S)= Hydroxychloroquine (H) combination therapy in rheumatoid arthritis (RA): Continued efficacy with minimal toxicity at 3 years Arthritis Rheum 39 Suppl 9 1996 123
10. J.R. O'Dell C. Haire N. Erikson Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate J Rheumatol 23 suppl 44 1996 72 74
11. J. O'Dell C. Haire N. Erikson Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications N Engl J Med 334 1996 1287 1291
12. J.R. O'Dell C.E. Haire W. Palmer Treatment of early rheumatoid arthritis with minocycline or placebo Arthritis Rheum 40 1997 842 848
13. J. O'Dell B. Nepom C. Haire DRB1 typing in rheumatoid arthritis (RA) is useful in predicting response to specific therapy Arthritis Rheum 39 Suppl 9 1996 305
14. H.E. Paulus M.J. Egger J.R. Ward Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo Arthritis Rheum 33 1990 477 484
15. R.S. Pinals A.T. Masi R.A. Larsen Preliminary criteria for clinical remission in rheumatoid arthritis Arthritis Rheum 24 1981 1308 1315
16. R. Rau G. Herborn H. Menninger Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients Br J Rheumatol 36 1997 345 352
17. B.C. Tilley G.S. Alarcon S.P. Heyse Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial Ann Intern Med 122 1995 81 89
18. P. Tugwell T. Pincus D. Yocum Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis N Engl J Med 333 1995 137 141
19. M.E. Weinblatt Methotrexate (MTX) in rheumatoid arthritis (RA): A 5-year multicenter prospective trial Arthritis Rheum 36 Suppl 1993 79